Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

NCT05593445 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05593445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05593445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 18, 2022
Completion date
December 21, 2023
Enrollment
61 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lichen sclerosus